Cell-permeable capsids as universal antigen carrier for the induction of an antigen-specific CD8+ T-cell response. 2017

Sami Akhras, and Masako Toda, and Klaus Boller, and Kiyoshi Himmelsbach, and Fabian Elgner, and Marlene Biehl, and Stephan Scheurer, and Meike Gratz, and Stefan Vieths, and Eberhard Hildt
Department of Virology, Paul-Ehrlich-Institut, 63225, Langen, Germany.

Vaccine platforms that can be flexibly loaded with antigens can contribute to decrease response time to emerging infections. For many pathogens and chronic infections, induction of a robust cytotoxic T lymphocytes-mediated response is desirable to control infection. Antigen delivery into the cytoplasm of antigen presenting cells favors induction of cytotoxic T cells. By fusion of the cell-permeable translocation motif (TLM)-peptide to the capsid-forming core protein of hepatitis B virus, and by insertion of the strep-tag in the spike tip (a domain that protrudes from the surface of the capsid), cell-permeable carrier capsids were generated that can be flexibly loaded with various antigens. Loading with antigens was demonstrated by electron microscopy, density gradient centrifugation and surface plasmon resonance spectroscopy. Confocal immunofluorescence microscopy showed that cell-permeable carrier capsids mediate transfer of cargo antigen into the cytoplasm. Using cell-permeable carrier capsids loaded with ovalbumin as model antigen, activation of antigen presenting cells and ovalbumin-specific CD8+ T-cells, which correlates with enhanced specific killing activity, was found. This demonstrates the capacity of TLM-carrier-capsids to serve as universal antigen carrier to deliver antigens into the cytoplasm of antigen presenting cells, which leads to enhanced MHC class I-mediated presentation and induction of antigen-specific cytotoxic T lymphocytes response.

UI MeSH Term Description Entries
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010047 Ovalbumin An albumin obtained from the white of eggs. It is a member of the serpin superfamily. Serpin B14
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002213 Capsid The outer protein protective shell of a virus, which protects the viral nucleic acid. Capsids are composed of repeating units (capsomers or capsomeres) of CAPSID PROTEINS which when assembled together form either an icosahedral or helical shape. Procapsid,Prohead,Capsids,Procapsids,Proheads
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D006512 Hepatitis B Core Antigens The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion. HBcAg,Hepatitis B Core Antigen
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000941 Antigens Substances that are recognized by the immune system and induce an immune reaction. Antigen
D014614 Vaccines, Synthetic Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. Antigens, Synthetic,Chemical Vaccine,Chemical Vaccines,Immunogens, Synthetic,Molecular Vaccine,Molecular Vaccines,Recombinant Vaccine,Semisynthetic Vaccine,Semisynthetic Vaccines,Synthetic Antigen,Synthetic Vaccine,Synthetic Vaccines,Vaccines, Recombinant,Synthetic Antigens,Synthetic Immunogens,Vaccines, Chemical,Vaccines, Molecular,Vaccines, Semisynthetic,Antigen, Synthetic,Recombinant Vaccines,Vaccine, Chemical,Vaccine, Molecular,Vaccine, Recombinant,Vaccine, Semisynthetic,Vaccine, Synthetic

Related Publications

Sami Akhras, and Masako Toda, and Klaus Boller, and Kiyoshi Himmelsbach, and Fabian Elgner, and Marlene Biehl, and Stephan Scheurer, and Meike Gratz, and Stefan Vieths, and Eberhard Hildt
June 2003, Infection and immunity,
Sami Akhras, and Masako Toda, and Klaus Boller, and Kiyoshi Himmelsbach, and Fabian Elgner, and Marlene Biehl, and Stephan Scheurer, and Meike Gratz, and Stefan Vieths, and Eberhard Hildt
December 2002, Journal of leukocyte biology,
Sami Akhras, and Masako Toda, and Klaus Boller, and Kiyoshi Himmelsbach, and Fabian Elgner, and Marlene Biehl, and Stephan Scheurer, and Meike Gratz, and Stefan Vieths, and Eberhard Hildt
July 2011, Journal of leukocyte biology,
Sami Akhras, and Masako Toda, and Klaus Boller, and Kiyoshi Himmelsbach, and Fabian Elgner, and Marlene Biehl, and Stephan Scheurer, and Meike Gratz, and Stefan Vieths, and Eberhard Hildt
March 1999, Immunology letters,
Sami Akhras, and Masako Toda, and Klaus Boller, and Kiyoshi Himmelsbach, and Fabian Elgner, and Marlene Biehl, and Stephan Scheurer, and Meike Gratz, and Stefan Vieths, and Eberhard Hildt
January 1979, La Ricerca in clinica e in laboratorio,
Sami Akhras, and Masako Toda, and Klaus Boller, and Kiyoshi Himmelsbach, and Fabian Elgner, and Marlene Biehl, and Stephan Scheurer, and Meike Gratz, and Stefan Vieths, and Eberhard Hildt
May 2000, Immunity,
Sami Akhras, and Masako Toda, and Klaus Boller, and Kiyoshi Himmelsbach, and Fabian Elgner, and Marlene Biehl, and Stephan Scheurer, and Meike Gratz, and Stefan Vieths, and Eberhard Hildt
May 2023, Journal for immunotherapy of cancer,
Sami Akhras, and Masako Toda, and Klaus Boller, and Kiyoshi Himmelsbach, and Fabian Elgner, and Marlene Biehl, and Stephan Scheurer, and Meike Gratz, and Stefan Vieths, and Eberhard Hildt
January 2022, Methods in molecular biology (Clifton, N.J.),
Sami Akhras, and Masako Toda, and Klaus Boller, and Kiyoshi Himmelsbach, and Fabian Elgner, and Marlene Biehl, and Stephan Scheurer, and Meike Gratz, and Stefan Vieths, and Eberhard Hildt
October 2005, Vaccine,
Sami Akhras, and Masako Toda, and Klaus Boller, and Kiyoshi Himmelsbach, and Fabian Elgner, and Marlene Biehl, and Stephan Scheurer, and Meike Gratz, and Stefan Vieths, and Eberhard Hildt
April 2001, Science (New York, N.Y.),
Copied contents to your clipboard!